Form 4: Recursion Pharmaceuticals Executive Reports Stock Transactio
Insider Transaction (Form 4)
David Hallett, Chief Scientific Officer of Recursion Pharmaceuticals, Inc., reported a transaction in 26,657 shares of common stock on August 17, 2026.
Summary
- Tax/exercise-price withholding: disposed of 26,657 Class A Common Stock at $3.16 ($84,236) on August 17, 2026; holds 1,043,837 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
David Hallett — Officer (Chief Scientific Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Tax/exercise-price withholding | Class A Common Stock | 26,657 | $3 | $84.2K | 1,043,837 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Tax/exercise-price withholding (26,657 shares) |
Keywords
insider transaction, Form 4, RXRX, RECURSION PHARMACEUTICALS, INC., neutral, David Hallett
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.